Genmab — Juni 2013
-
som Victoza
-
aka linket til slides er i hovedforummet. ikke herinde
-
Volume market share on weekly basis
-
8,1% market share i germany
-
i volume
-
meget spændnede
-
i UK er der normalt barrierer med nye produkter. De har target alle disse barrierer. De har allerede nået 50% af alle de targets. "key formary listings"
-
de har nået næsten 90% targeting af dem de vil i UK allerede.
-
De stopper ikke med data. De kører stadig en del phase IIIb studier med Lyxumia, også som mono
-
tror ikke
-
Nu om LixiLan
-
Phase IIb proof of concept studiet har gode resultater
-
across criterias
-
phase III start i H1 2014
-
De tror de bliver den første i US.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind